Co-Immune

Co-Immune is a clinical-stage biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company's core technology, the Arcelis platform, utilizes a patient's own dendritic cells to trigger a robust immune response against specific disease targets. Co-Immune's lead program, CMN-001, is an autologous dendritic cell-based immunotherapy currently in Phase 3 clinical trials for the treatment of metastatic renal cell carcinoma. Additionally, the company is advancing a pipeline of CAR-T cell therapies and treatments for chronic viral infections like HIV. Co-Immune was formed through the acquisition of the assets of Argos Therapeutics, leveraging established manufacturing infrastructure and clinical data.